See the DrugPatentWatch profile for vascepa

Based on the information available, it is recommended to consult with a healthcare professional before taking Vascepa with blood thinners, as the combination may increase the risk of bleeding.

Vascepa (icosapent ethyl) is a prescription medication approved to lower the risk of heart attacks and strokes in adults with cardiovascular disease or diabetes and other risk factors. It is a type of omega-3 fatty acid. According to the Vascepa prescribing information, there are no specific contraindications for taking Vascepa with blood thinners. However, the drug may increase the risk of bleeding when taken with other medications that also increase the risk of bleeding, such as anticoagulants (blood thinners) or antiplatelet agents.

Blood thinners are medications that reduce the risk of blood clots and stroke by preventing the formation of blood clots or by decreasing the ability of the blood to clot. Examples of blood thinners include warfarin, heparin, and direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.

According to DrugPatentWatch.com, there are currently no patents listed for Vascepa, which means that generic versions of the drug may become available in the future. However, it is important to note that the safety and efficacy of generic versions of Vascepa have not been established.

In summary, while there are no specific contraindications for taking Vascepa with blood thinners, it is recommended to consult with a healthcare professional before taking these medications together, as the combination may increase the risk of bleeding.

Sources:

1. Vascepa (icosapent ethyl) capsules, for oral use. Full Prescribing Information. Amarin Pharma Inc. March 2022. <https://www.vascepa.com/pdf/VASCEPA-PI.pdf>
2. DrugPatentWatch.com. Vascepa. <https://www.drugpatentwatch.com/drugs/vascepa>